That's great news! Here's some more information about breakthroughs for Rett and Dravet syndromes.

For Rett syndrome, Trofinetide (Daybue) is the first FDA-approved treatment, improving behavior, communication, mood, breathing, and hand movements. Researchers are also looking into gene replacement therapies as potential cures.

In Dravet syndrome, gene replacement therapy targeting SCN1A has shown promise in mouse models. TAU depletion has also been effective in reducing seizures and improving survival. Zorevunersen has demonstrated sustained seizure reductions and improvements in behavior and cognition in patients. You can find more information on the Emperor study [https://www.emperorstudy.com/].